Kiora Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies aimed at treating rare and complex diseases
The company specializes in advancing drug candidates that utilize unique formulations and targeted delivery mechanisms to improve patient outcomes. Kiora's research and development efforts are centered on addressing unmet medical needs through a combination of proprietary approaches and strategic collaborations. By leveraging cutting-edge technology and scientific expertise, the company strives to bring effective treatments to market for conditions with limited therapeutic options.
Topline Phase I/II First-in-Human Results Presented at AAO 2023Significant improvement in visual field, in concordance with trended improvements in visual...
Kiora Pharmaceuticals Inc. (NASDAQKPRX) traded today at a new 52-week high of $6.65. Approximately 147,000 shares have changed hands today, as compared to an average 30-day volume of 19 million shares.
Encinitas, California--(Newsfile Corp. - August 22, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQKPRX), a clinical-stage biotechnology company developing novel therapies...
San Diego, CA -- (SBWIRE) -- 02/15/2022 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares over potential securities laws violations by Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 12/15/2021 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares over potential securities laws violations by Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 12/01/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc. .
